MOTE Therapeutics (referred as MOTE), a seed-stage biotech developing targeted RNA delivery solutions, announced the appointment of MaryJane Rafii, PhD, MBA, as Chief Investment and Business Officer.

With Terrana Biosciences, Moderna founder Flagship can apply its RNA knowledge to agricultural use cases like pest and ...

This article makes a valuable contribution to the field by uncovering a molecular mechanism for miRNA intracellular retention, mediated by the interaction of PCBP2, SYNCRIP, and specific miRNA motifs.

While biopharmaceutical technologies have made substantial strides in treating diseases, drug research and development ...

A University of California, Riverside-led team has made an advance in the basic understanding of Plasmodium falciparum, the ...

The innate immune system is the body's first line of defense against pathogens and foreign substances. An essential component of this system are pattern recognition receptors, which recognize non-self ...

Terrana Biosciences will develop crop protection inputs using RNA technology, which was used by Flagship portfolio company Moderna to develop its covid-19 vaccine.

With a $50 million initial investment from Flagship, Terrana will use RNA from benign plant viruses as a chassis to carry ...

Assessing the distribution of a medication in the brain is critical for the treatment of a vast range of neurological ...

Terrana is aiming to have commercially available products in the next few years, pending regulatory approval, that can be applied as sprayables or seed treatments. And the company says its RNA-based ...